What alternative treatments can reduce intraocular pressure without using topical eye drops?

Alternative Methods to Reduce Intraocular Pressure Beyond Topical Medications

Laser trabeculoplasty (either selective or argon) should be your first-line alternative to topical medications, as it provides comparable IOP reduction to prostaglandin analogs and can be considered as initial therapy in selected patients. 1

Laser Procedures

Selective Laser Trabeculoplasty (SLT)

• Most commonly used laser alternative with comparable efficacy to topical prostaglandin analogs 1
• Uses 532 nm Q-switched Nd:YAG laser that selectively targets pigmented trabecular meshwork cells
• Produces less thermal damage than older argon laser trabeculoplasty (ALT)
• IOP reduction: Typically 9 mmHg reduction, similar to timolol 1
• Can treat 180° or 360° of trabecular meshwork
• Safety profile: Mild anterior chamber inflammation, IOP spikes in 4.5-27% of cases 1
• Particularly useful for patients with adherence issues, cost concerns, or medication intolerance 1

Argon Laser Trabeculoplasty (ALT)

• Provides clinically significant IOP reduction in >75% of initial treatments 1
• Long-term data shows 30-50% require additional surgery within 5 years 1
• Repeat ALT has lower success rates (90% failure by 2 years) 1

Clinical Pearl: SLT and ALT show equivalent IOP-lowering efficacy, but SLT may have advantages for repeat treatments 2

Minimally Invasive Glaucoma Surgery (MIGS)

These procedures use an ab interno approach with minimal tissue trauma 1:

iStent (Trabecular Microbypass)

• FDA-approved for combination with cataract extraction in mild-to-moderate open-angle glaucoma 1
• Heparin-coated titanium device implanted into Schlemm's canal
• IOP reduction: Modest, typically to mid-to-upper teens 1
• Multiple stents provide better IOP lowering than single stent 1
• Low complication rates (mainly stent malposition/obstruction) 1

Trabectome (Ab Interno Trabeculectomy)

• Removes trabecular meshwork strip using high-frequency electrocautery 1
• Reduces IOP and medication burden with minimal complications 1
• Prior laser trabeculoplasty doesn't affect outcomes 1

Important Limitation: MIGS procedures are less effective than trabeculectomy or aqueous shunts but have superior short-term safety profiles 1

Traditional Incisional Surgery

Trabeculectomy

• Most effective IOP reduction (48-60% reduction in clinical trials) 1
• Creates new drainage pathway for aqueous humor
• Higher complication risk than MIGS but superior long-term IOP control
• Requires lifelong endophthalmitis risk monitoring 1

Aqueous Shunt Surgery

• Alternative when trabeculectomy fails or is contraindicated
• Comparable efficacy to trabeculectomy in many cases 2

Cyclodestructive Surgery

• Reduces aqueous production by destroying ciliary body function 1
• Reserved for refractory cases

Emerging Non-Surgical Options

Sustained-Release Intracameral Implants

• Bimatoprost implant: Single administration, effects last ~12 months 3, 4, 5
• Travoprost implant: Single administration, effects last ~36 months 3, 4, 5
• Both demonstrate non-inferior IOP reduction compared to timolol drops 3
• Major advantage: Eliminates daily drop burden and adherence issues
• Concern: Corneal endothelial cell loss requires monitoring 5

Direct Selective Laser Trabeculoplasty (DSLT)

• FDA-approved newer technique applying laser through limbus in 2 seconds 4
• Reduces procedure duration significantly

Ocular Pressure Adjusting Pump

• Non-invasive, non-pharmaceutical wearable device (goggles) 4
• Lowers IOP using negative pressure
• Eliminates medication side effects

Clinical Decision Algorithm

For newly diagnosed patients or those intolerant to drops:

1. Consider SLT as initial therapy (comparable to prostaglandin drops) 1
2. If combined with cataract, add iStent for additional IOP reduction 1

For patients with adherence issues:

1. Intracameral implants (bimatoprost or travoprost) for 1-3 years of coverage 3, 4, 5
2. SLT as alternative if implants contraindicated

For inadequate response to medications/laser:

1. MIGS if mild-moderate disease and acceptable IOP target in mid-upper teens 1
2. Trabeculectomy or aqueous shunt for more aggressive IOP lowering needed 1, 2

Critical Caveat: While MIGS has better safety profiles, it provides less IOP reduction than traditional surgery. Match the intervention intensity to disease severity and target IOP requirements 1.